Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Total Current Liabilities (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Total Current Liabilities for 13 consecutive years, with $310.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 83.3% to $310.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $310.3 million, a 83.3% increase, with the full-year FY2025 number at $310.3 million, up 83.3% from a year prior.
  • Total Current Liabilities was $310.3 million for Q4 2025 at Madrigal Pharmaceuticals, down from $391.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $391.4 million in Q3 2025 to a low of $48.8 million in Q1 2021.
  • A 5-year average of $134.8 million and a median of $107.0 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: increased 0.75% in 2023, then soared 120.08% in 2025.
  • Madrigal Pharmaceuticals' Total Current Liabilities stood at $76.8 million in 2021, then skyrocketed by 50.83% to $115.9 million in 2022, then rose by 2.29% to $118.5 million in 2023, then surged by 42.79% to $169.3 million in 2024, then skyrocketed by 83.3% to $310.3 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Total Current Liabilities are $310.3 million (Q4 2025), $391.4 million (Q3 2025), and $196.5 million (Q2 2025).